<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548361" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548361/" /><meta name="ncbi_pagename" content="Sulfonylureas - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Sulfonylureas - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Sulfonylureas" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2018/03/16" /><meta name="citation_pmid" content="31643682" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548361/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Sulfonylureas" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2018/03/16" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548361/" /><meta name="description" content="The sulfonylureas are a class of agents that lower blood sugar as a result of increasing release of insulin from the pancreas. The sulfonylureas are used for the therapy of mild-to-moderate type 2 diabetes in conjunction with diet, and can be used alone or in combination with metformin, thiazolidinediones or other hypoglycemic agents. The sulfonylureas have been associated with rare cases of idiosyncratic drug induced liver disease with somewhat similar pattern of onset, injury and outcome." /><meta name="og:title" content="Sulfonylureas" /><meta name="og:type" content="book" /><meta name="og:description" content="The sulfonylureas are a class of agents that lower blood sugar as a result of increasing release of insulin from the pancreas. The sulfonylureas are used for the therapy of mild-to-moderate type 2 diabetes in conjunction with diet, and can be used alone or in combination with metformin, thiazolidinediones or other hypoglycemic agents. The sulfonylureas have been associated with rare cases of idiosyncratic drug induced liver disease with somewhat similar pattern of onset, injury and outcome." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548361/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Sulfonylureas/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548361/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88592A046891910000000002A900BE.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548361_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548361_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Sulfonamides/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/FstGenSulfonylureas/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548361_"><span class="title" itemprop="name">Sulfonylureas</span></h1><p class="small">Last Update: <span itemprop="dateModified">March 16, 2018</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Sulfonylureas.OVERVIEW"><h2 id="_Sulfonylureas_OVERVIEW_">OVERVIEW</h2><p>The sulfonylureas are a class of agents that lower blood sugar as a result of increasing release of insulin from the pancreas. The sulfonylureas are used for the therapy of mild-to-moderate type 2 diabetes in conjunction with diet, and can be used alone or in combination with metformin, thiazolidinediones or other hypoglycemic agents. The sulfonylureas have been associated with rare cases of idiosyncratic drug induced liver disease with somewhat similar pattern of onset, injury and outcome.</p><p>While the sulfonylureas are derivatives of sulfonamides, they have no intrinsic antibacterial activity. They are believed to lower blood glucose levels by stimulating insulin release from pancreatic beta cells. However, their effects on blood glucose with chronic therapy are more complex, and the sulfonylureas may have extra-pancreatic actions that affect blood sugar, reducing hepatic clearance of insulin or increasing insulin sensitivity. The sulfonylureas have little effect in type 1 diabetes, in which there is a deficiency in insulin producing pancreatic beta cells. The sulfonylureas are widely used and are generally considered a first line of medication therapy for type 2 diabetes.</p><p>The sulfonylureas are divided into first and second generation agents, based upon their relative potency. All sulfonylureas share a similar structure, being substituted arylsulfonylureas. They differ on the basis of substitutions at the para positions at the two ends of the arylsulfonylurea molecule. The first generation sulfonylureas include chlorpropamide, tolazamide and tolbutamide. These agents are now rarely used although still available in the United States. The second generation sulfonylureas include gliclazide, glimepiride, glipizide and glyburide (known as glibenclamide outside of the United States) which are active in lower concentrations, are effective when taken once daily and have fewer of the troublesome dose related side effects of the first generation sulfonylureas, such as headache, nausea, anorexia, fatigue and paresthesias. The sulfonylureas (particularly the first generation agents) can also cause alcohol intolerance (flushing) through inhibition of alcohol dehydrogenase. The sulfonylureas are all labelled with a warning of increased risk of cardiovascular mortality with long term use.</p><p>For discussion of their current use, chemical structure and hepatotoxicity, the sulfonylureas are discussed individually in the sections on first or second generation agents. References and case examples are given below in this Overview section.</p><p>Drug Class: <a href="/books/n/livertox/Antidiabetic/">Antidiabetic Agents</a></p><p>Drugs in the Subclass Sulfonylureas: <a href="/books/n/livertox/FstGenSulfonylureas/">First Generation Sulfonylureas</a>, <a href="/books/n/livertox/SndGenSulfonylureas/">Second Generation Sulfonylureas</a></p></div><div id="Sulfonylureas.CASE_REPORTS"><h2 id="_Sulfonylureas_CASE_REPORTS_">CASE REPORTS</h2><div id="Sulfonylureas.Case_1._Immunoallergic_cho"><h3>Case 1. Immunoallergic cholestatic hepatitis due chlorpropamide with cross sensitivity to tolbutamide, but not glyburide.</h3><p>[Modified from: Rumboldt Z, Bota B. Favorable effects of glibenclamide in a patient exhibiting idiosyncratic hepatotoxic reactions to both chlorpropamide and tolbutamide. Acta Diabetol Lat 1984; 21: 387-91. <a href="https://www.ncbi.nlm.nih.gov/pubmed/6442088" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 42 year old woman developed rash, fever, abdominal pain and jaundice 4 weeks after starting chlorpropamide and a few days after receiving ampicillin. She was anicteric but had low grade fevers and a pruritic maculopapular rash over the chest, arms and legs. Ampicillin was stopped and corticosteroids started while the chlorpropamide was continued. The fever improved and rash began to fade, but she then redeveloped high fevers and became jaundiced with worsening alkaline phosphatase elevations and eosinophilia (Table). Ultrasonography showed no biliary abnormalities. Insulin was substituted for chlorpropamide, and antibiotics were started. Both her fever and abnormal liver tests resolved. A challenge dose of chlorpropamide was given and she promptly developed rash, fever and abdominal pain (with only mild increases in liver test results). She was switched to tolbutamide (100 mg daily) and did well until 4 weeks later when she redeveloped fever and jaundice. Tolbutamide was stopped and she improved while maintained on insulin. Two months later glyburide (glibenclamide) was started. Over the next four months she remained well without fever or laboratory test abnormalities.</p><div id="Sulfonylureas.Key_Points1"><h4>Key Points</h4><div id="Sulfonylureas.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548361/table/Sulfonylureas.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Sulfonylureas.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Chlorpropamide (Diabinese: 500 mg daily)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Cholestatic (R=&#x0003c;1.0)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">3+ (hospitalization for jaundice)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</td><td rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Delayed by rechallenge</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Ampicillin</td></tr></tbody></table></div></div></div><div id="Sulfonylureas.Laboratory_Values1"><h4>Laboratory Values</h4><div id="Sulfonylureas.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548361/table/Sulfonylureas.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Sulfonylureas.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (U/L)</th><th id="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a>* (mg/dL)</th><th id="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">178</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">50</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.6</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Ampicillin stopped</td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">5 weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">177</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">313</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">5.7</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Chlorpropamide stopped</td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">5 weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">280</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">453</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">4.8</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">6 weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">1 week</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">241</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">4.4</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">7 weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">70</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.9</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">8 weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">3 weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">58</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">61</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.6</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">9 weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">49</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">158</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.9</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Chlorpropamide challenge</td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">10 weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">5 weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">22</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">63</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.2</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Tolbutamide started</td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">12[2] weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">7 weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">22</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">24</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.0</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">15[5] weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">10[0] weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">93</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">72</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.7</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Tolbutamide stopped</td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">26[16] weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">21[11] weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">19</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">22</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.9</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Glyburide started</td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">30[20] weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">25[15] weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">18</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">21</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.8</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">40[30] weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">35[25] weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">19</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">62</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.6</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">44[34] weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">39[29] weeks</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">16</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">28</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.7</td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T2_1_1_1_1 hd_h_Sulfonylureas.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Sulfonylureas.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;25</b></td><td headers="hd_h_Sulfonylureas.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;30</b></td><td headers="hd_h_Sulfonylureas.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Sulfonylureas.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div><p>* Converted from &#x003bc;mol: 1 mg/dL=17.1 &#x003bc;mol. Times in brackets refer to weeks after starting or stopping tolbutamide.</p></div><div id="Sulfonylureas.Comment1"><h4>Comment</h4><p>The patient developed signs of hypersensitivity (fever, rash, eosinophilia) and mild cholestatic liver injury after 4 weeks of chlorpropamide therapy. The rash and fever were initially attributed to ampicillin, but fevers returned and frank jaundice appeared while chlorpropamide was continued. She improved once chlorpropamide was stopped (also while receiving corticosteroids) and had an immediate recurrence upon rechallenge (fever, rash and abdominal pain), providing convincing evidence for the role of chlorpropamide in the immunoallergic hepatitis. Interestingly, there was a recurrence with a similar pattern of onset (~4 weeks) and injury with tolbutamide (another first generation sulfonylurea), but not with glyburide (called glibenclamide in Europe; a second generation sulfonylurea). The liver injury associated with first generation sulfonylureas varies greatly in clinical presentation, but typically arises after 2 to 8 weeks of therapy, is predominantly cholestatic, mild-to-moderate in severity, and associated with features of hypersensitivity in up to half of cases.</p></div></div><div id="Sulfonylureas.Case_2._Acute_hepatitis_du"><h3>Case 2. Acute hepatitis due to gliclazide.</h3><p>[Modified from: Chitturi S, Le V, Kench J, Loh C, George J. Gliclazide-induced acute hepatitis with hypersensitivity features. Dig Dis Sci 2002; 47: 1107-10. <a href="https://www.ncbi.nlm.nih.gov/pubmed/12018908" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 42 year old woman developed rash and pruritus 4 weeks after starting metformin and gliclazide for newly diagnosed type 2 diabetes. She was treated with antihistamines and topical agents and improved, but two weeks later routine testing revealed marked elevations in liver tests. She had no history of drug reactions, alcohol abuse or risk factors for viral hepatitis. At the time of her initial diagnosis of diabetes and before starting medications, her liver enzymes were mildly elevated (<a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> 61 U/L, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> 95 U/L, alkaline phosphatase 78 U/L), but she had no symptoms of liver disease and had no history of jaundice or other significant medical illnesses. Her only other medications were oral contraceptives that she had been using for 3 years. Six weeks after starting antidiabetic medications, laboratory tests showed a total bilirubin of 2.9 mg/dL, ALT 1605 U/L, alkaline phosphatase 158 U/L and eosinophils 18% (absolute count 1390/&#x003bc;L). Physical examination was unrevealing; her skin rash had resolved. Metformin was thought to be the cause of the liver injury and was stopped. Over the next few days, however, she became noticeably jaundiced and bilirubin levels rose (Table). Gliclazide was stopped. When her prothrombin time was found to be abnormal (21 seconds), she was admitted for observation. Tests for hepatitis A, B and C (including HCV RNA) were negative as were autoantibodies, although serum immunoglobulin levels were mildly elevated (IgG 2310 mg/dL, total serum globulins 4.6 g/dL). A liver biopsy showed fibrosis and regenerative nodules consistent with cirrhosis along with focal necrosis, moderate inflammation, Mallory's hyaline and prominent ballooning degeneration, suggestive of an underlying nonacloholic steatohepatitis with a superimmposed acute drug induced liver injury. Once glicazide was stopped, liver tests began to improve and were normal within a few weeks. Metformin was then reintroduced and serum enzymes remained normal.</p><div id="Sulfonylureas.Key_Points2"><h4>Key Points</h4><div id="Sulfonylureas.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548361/table/Sulfonylureas.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Sulfonylureas.T3_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Medication:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Gliclazide (80 mg twice daily)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (R=29)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Severity:</td><td rowspan="1" colspan="1" style="vertical-align:top;">4+ (jaundice and prolongation of prothrombin time)</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</td><td rowspan="1" colspan="1" style="vertical-align:top;">6 weeks</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</td><td rowspan="1" colspan="1" style="vertical-align:top;">1 month</td></tr><tr><td rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</td><td rowspan="1" colspan="1" style="vertical-align:top;">Metformin, fexofenadine (for rash), oral contraceptives</td></tr></tbody></table></div></div></div><div id="Sulfonylureas.Laboratory_Values2"><h4>Laboratory Values</h4><div id="Sulfonylureas.T4" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548361/table/Sulfonylureas.T4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Sulfonylureas.T4_lrgtbl__"><table><thead><tr><th id="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a>* (U/L)</th><th id="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a>* (mg/dL)</th><th id="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pre</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">61</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">78</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">Normal</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Diagnosis</td></tr><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3 hd_h_Sulfonylureas.T4_1_1_1_4 hd_h_Sulfonylureas.T4_1_1_1_5 hd_h_Sulfonylureas.T4_1_1_1_6" colspan="4" rowspan="1" style="vertical-align:top;">Rash and pruritus</td></tr><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">6 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1605</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">158</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.9</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Metformin stopped</td></tr><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">3 days</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">2598</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">4.7</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Gliclazide stopped</td></tr><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">7 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">7 days</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">2300</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">7.8</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Protime 21 sec</td></tr><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">10 days</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">2200</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">8.4</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Liver biopsy</td></tr><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">8 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">450</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">3.0</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">10 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">40</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.2</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">11 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">5 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">25</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.1</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">13 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">7 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">25</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.0</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Metformin restarted</td></tr><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">14 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">8 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">25</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.8</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">16 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">10 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">25</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.7</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">24 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">18 weeks</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">25</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.6</td><td headers="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Sulfonylureas.T4_1_1_1_1 hd_h_Sulfonylureas.T4_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;40</b></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;115</b></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Sulfonylureas.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div><p>* Some values and times estimated from Figure 4.</p></div><div id="Sulfonylureas.Comment2"><h4>Comment</h4><p>This patient with type 2 diabetes appeared to have preexisting nonalcoholic steatohepatitis. At the time of the initial diagnosis of diabetes, her serum aminotransferase levels were elevated and a liver biopsy taken at the height of the acute injury demonstrated fibrosis and regenerative nodules indicative of an incomplete cirrhosis, while the prominent ballooning degeneration and Mallory's hyaline suggested the cause to be steatohepatitis. The timing of onset of jaundice, 6 weeks after starting gliclazide, the mild immunoallergic features (rash, eosinophilia), and rapid improvement after discontinuation are highly suggestive of sulfonylurea induced acute liver injury. Metformin was initially thought to be the cause, but stopping it did not result in rapid improvement and she later tolerated reintroduction without a rise in serum enzymes. Indeed, metformin has been used as therapy of nonalcoholic steatohepatitis, although its effects may be largely the result of weight loss, which is typical of metformin. Patients with nonalcoholic steatohepatitis are often considered to be at a higher risk for drug induced liver injury, but they probably are just more likely to have a more severe course if the idiosyncratic injury arises. This patient should be warned against the use of other sulfonylureas. Whether she is at higher risk of hypersensitivity reactions to other sulfa containing drugs (sulfonamides, celecoxib) is unknown.</p></div></div></div><div id="Sulfonylureas.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Sulfonylureas_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 16 March 2018</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Sulfonylureas.R1">Zimmerman HJ. Oral hypoglycemic agents and other diabetes therapy. In, Zimmerman, HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott,1999: pp. 575-79.<div><i>(Expert review of sulfonylureas and liver injury published in 1999 which are described as having a low rate of hepatic complications with variable presentation).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R2">De Marzio DH, Navarro VJ. Sulfonylureas. Hepatotoxicity of cardiovascular and antidiabetic drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 529.<div><i>(Review of hepatotoxicity of drugs for diabetes including first and second generation sulfonylureas).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R3">Powers AC, D'Alessio D. Therapy of diabetes. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1248-67.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R4">Brown G, Zoidis J, Spring M. Hepatic damage during chlorpropamide therapy. JAMA 1959; 170: 2085. Not in Pub Med. [<a href="/pubmed/13672807" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13672807</span></a>]<div><i>(Three women, ages 50, 67 and 57 years, with onset of liver injury after 3-6 weeks of chlorpropamide therapy, two with jaundice [bilirubin 0.2-8.9 mg/dL, Alk P 2-7 times ULN, ALT not available], resolving in all three within 2-5 weeks of stopping; one patient had fever, rash and eosinophilia).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R5">Hadley WB, Kachadurian A, Marble A. Studies with chlorpropamide in diabetic patients. Ann NY Acad Sci 1959; 74: 621-4.  [<a href="/pubmed/13637600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13637600</span></a>]<div><i>(Analysis of 72 patients given chlorpropamide; one developed jaundice after 3 weeks [bilirubin 3.9 mg/dL, ALT not done, Alk P 4 times ULN, eosinophils 10%], biopsy showed intrahepatic cholestasis, resolving within 2 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R6">Hamff IH, Ferris AH, Evans EC, Whiteman HW. The effect of tolbutamide and chlorpropamide on patients exhibiting jaundice as a result of previous chlorpropamide therapy. Ann NY Acad Sci 1959; 74: 820-9.  [<a href="/pubmed/13637623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13637623</span></a>]<div><i>(Three case reports of jaundice arising 2-4 weeks after starting chlorpropamide [bilirubin 1.9-10.7 mg/dL, Alk P 2-7 times ULN, ALT not available], resolving within 4-8 weeks of stopping, and no recurrence on starting tolbutamide or restarting chlorpropamide at lower doses).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R7">Reichel J, Goldberg SB, Ellenberg M, Schaffner F. Intrahepatic cholestasis following administration of chlorpropamide. Report of a case with electron microscopic observations. Am J Med 1960; 28: 654-60.  [<a href="/pubmed/14437049" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14437049</span></a>]<div><i>(67 year old woman developed jaundice and itching 8 weeks after starting chlorpropamide [bilirubin 30 mg/dL, AST 91 U/L, Alk P 26.2 KA U/L], biopsy showed intrahepatic cholestasis, resolving within 2 months of stopping; weakly positive rechallenge to chlorpropamide, not to tolbutamide).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R8">Baird RW, Hull JG. Cholestatic jaundice from tolbutamide. Ann Intern Med 1960; 53: 194.  [<a href="/pubmed/13795916" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13795916</span></a>]<div><i>(57 year old man developed jaundice after intermittent use of tolbutamide for 8 weeks [bilirubin 7.7 mg/dL, AST 260 U/L, Alk P 2 times ULN], underwent emergency laparotomy, but ultimately recovered).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R9">McMahon TF. Cholestatic jaundice, liver decompensation, and shock resulting from tolbutamide: report of a case. Med Ann DC 1963; 509.  [<a href="/pubmed/14086226" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14086226</span></a>]<div><i>(50 year old man developed jaundice and ascites after being on tolbutamide for 3 years; whiskey bottles found in his room; no information on liver enzymes or histology).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R10">Stocchi F, Mastrilli B. [Contribution to the study of jaundice caused by intrahepatic cholestasis of drug origin: forms of chlorpropamide and sulfamethoxypyridazine.] Clin Ter 1962; 22: 925-32. Italian.  [<a href="/pubmed/13917277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13917277</span></a>]<div><i>(75 year old man developed jaundice 10 days after starting chlorpropamide [bilirubin 14.2 mg/dL, ALT 30 U/L, Alk P 2.5 times ULN], resolving within 2 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R11">Arteaga A, Valdicieso V, Etchart M. [Hepatic function in patients treated with Chlorpropamide for prolonged periods.] Rev Med Chil 1964; 92: 450-5. Spanish.  [<a href="/pubmed/14208075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14208075</span></a>]</div></li><li><div class="bk_ref" id="Sulfonylureas.R12">Ciammaichella A, Cantera N. [Contribution to the study of the toxic effects due to hypoglycemic sulfonylureas.] Minerva Med 1964; 55: 657-64. Italian.  [<a href="/pubmed/14140236" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14140236</span></a>]<div><i>(Review of literature and three case reports: Case 1 was a 58 year old woman who developed fever and rash 3 weeks after starting chlorpropamide, followed by jaundice [bilirubin 10.7 mg/dL, Alk P 6 times ULN], resolving rapidly and not recurring when restarted at lower dose; Case 2 was a 68 year old woman who developed symptoms, rash and fever 2 weeks after starting chlorpropamide [bilirubin 6.4 mg/dL, Alk P 2 times ULN], resolving rapidly and not recurring when restarted at lower dose; Case 3 was a 50 year old woman who developed symptoms within 3 days of starting chlorpropamide with eosinophilia, later tolerating tolbutamide, but redeveloping symptoms on restarting chlorpropamide).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R13">Ciammaichella A, Cantera N. [Jaundice during oral antidiabetic therapy.] Fegato 1963; 18: 444-56. Italian.  [<a href="/pubmed/14117143" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14117143</span></a>]<div><i>(Similar review and description of 3 cases of sulfonylurea hepatotoxicity as in Ciammaichella [1964]).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R14">Haunz EA, Cornatzer WE, Luper M, Forks G. Liver function in Chlorpropamide therapy. Five year clinical study of 181 patients. JAMA 1964; 188: 237-40.  [<a href="/pubmed/14113990" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14113990</span></a>]<div><i>(Summary of routine liver tests done on 181 patients treated with chlorpropamide for 1 week to 5 years, 125-750 mg/day, ~5% had minor, transient AST elevations (&#x0003c;2 times ULN), ~7% had mild, transient Alk P elevations).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R15">Ostman J, Groenberg A. [Side-effects in the oral treatment of diabetes with sulfonylureas.] Nord Med 1964; 72: 1388-95. Swedish.  [<a href="/pubmed/14210083" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14210083</span></a>]<div><i>(Review and summary of published literature on side effects of sulfonylureas).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R16">Collens WS, Dobkin GB. Cholestatic jaundice following use of sulfonylurea drugs. N Y State J Med 1965; 65: 907-9.  [<a href="/pubmed/14265335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14265335</span></a>]<div><i>(21 year old man developed nausea after 1 week and jaundice after 3 weeks of chlorpropamide therapy, with rapid resolution upon stopping; starting tolbutamide led to recurrence 5 weeks later [bilirubin 4.5 mg/dL, ALT 210 U/L, Alk P 2.5 times ULN], resolving within a few months).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R17">Ferrero E, Marioni G, Antognetti R, Falchi F. [Tolazamide and hepatic damage] Minerva Med 1965; 56: 3609-13. Italian.  [<a href="/pubmed/5841666" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5841666</span></a>]</div></li><li><div class="bk_ref" id="Sulfonylureas.R18">Goldstein MJ, Rothenberg AJ. Jaundice in a patient receiving acetohexamide. N Engl J Med 1966; 275: 97-9.  [<a href="/pubmed/5936873" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5936873</span></a>]<div><i>(58 year old man developed jaundice 3 weeks after starting acetohexamide [bilirubin 20.7 mg/dL, ALT 630 U/L, Alk P 4 times ULN]; biopsy showed cirrhosis, no recurrence with restarting acetohexamide).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R19">Grottum KA. [Liver damage due to phenylbutazone and chlorpropamide] Tidsskr Nor Laegeforen 1966; 86: 1096-8. Norwegian.  [<a href="/pubmed/5919203" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5919203</span></a>]</div></li><li><div class="bk_ref" id="Sulfonylureas.R20">Balodimos MC, Camerini-D&#x000e1;valos RA, Marble A. Nine years. experience with tolbutamide in the treatment of diabetes. Metabolism 1966; 15: 957-70.  [<a href="/pubmed/5950894" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5950894</span></a>]<div><i>(Experience in using tolbutamide in 3644 diabetic patients at Joslin Clinic over 9 years; 4 cases of untoward liver events, possibly due to tolbutamide; one case of jaundice after 3 months with progressive liver failure and death).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R21">Henderson BE, Field RA. Evaluation of hepatic function during long-term Chlorpropamide therapy. Pa Med 1967; 70: 61-2.  [<a href="/pubmed/6065567" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6065567</span></a>]<div><i>(Testing of 20 patients on long term [&#x0003e;3 years] therapy with chlorpropamide [500 mg/day] found normal levels of AST in all, normal Alk P in 90% and normal BSP retention in 80%; "..granted the number of patients evaluated was small..").</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R22">Gregory DH, Zaki GF, Sarosi GA, Carey JB Jr. Chronic cholestasis following prolonged tolbutamide administration. Arch Pathol 1967; 84: 194. (Not in PubMed) [<a href="/pubmed/21936121" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21936121</span></a>]<div><i>(48 year old woman developed jaundice 12 months after starting tolbutamide, which was continued for another 12 months when she was found to have bilirubin 20.5 mg/dL, ALT 103 U/L, Alk P 64 KA/L, dying shortly thereafter of hepatic failure; autopsy showed ductopenia, severe cholestasis, but scant necrosis; no mention of AMA testing).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R23">Rotolo V. [Jaundice in diabetics treated with sulfonylureas. On a clinical case of jaundice caused by tolazamide] Friuli Med 1968; 23: 257-75. Italian.  [<a href="/pubmed/5747401" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5747401</span></a>]<div><i>(Review of hepatotoxicity of sulfonylureas and case of jaundice arising after 3 months of tolazamide therapy [bilirubin 8.0 rising to 18 mg/dL, ALT 200 U/L, Alk P ~2 times ULN], biopsy showing acute injury; repeat, follow up biopsy showing recovery).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R24">Ananth JV, Ban TA, Lehmann HE. Tolbutamide jaundice associated with multiple drug therapy. Can Med Assoc J 1970; 103: 1194.  [<a href="/pmc/articles/PMC1930613/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1930613</span></a>] [<a href="/pubmed/5489326" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5489326</span></a>]<div><i>(Complex case of itching and jaundice arising after uncertain duration [?4 years] of tolbutamide therapy and brief use of thioridazine [bilirubin 5.5 mg/dL, AST 13.8 and Alk P 10.4 unknown units], with rechallenge jaundice was said to return, but bilirubin was 1.1 mg/dL).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R25">de Baere H, Decraene P, de Leeuw I, Lemmens P, Verhaegen H. [Hypoglycemia caused by oral antidiabetic agents] Ned Tijdschr Geneeskd 1973; 117: 1021-4. Dutch.  [<a href="/pubmed/4206176" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4206176</span></a>]</div></li><li><div class="bk_ref" id="Sulfonylureas.R26">Van Thiel DH, De Belle R, Mellow M, Widerlite L, Philipps E. Tolazamide hepatotoxicity. A case report. Gastroenterology 1974; 67: 506-10.  [<a href="/pubmed/4855219" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4855219</span></a>]<div><i>(62 year old man developed jaundice 4 weeks after starting tolazamide that was continued for another month [bilirubin rising from 8.9 to 16.5 mg/dL, AST 50 U/L, Alk P 180 U/L], resolving within 2 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R27">Clarke BF, Campbell IW, Ewing DJ, Beveridge GW, MacDonald MK. Generalized hypersensitivity reaction and visceral arteritis with fatal outcome during glibenclamide therapy. Diabetes 1974; 23: 739-42.  [<a href="/pubmed/4213123" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4213123</span></a>]<div><i>(67 year old man developed fever, rash and jaundice 4 weeks after starting glyburide [peak bilirubin 12.2 mg/dL, ALT 152 U/L, Alk P 125 KA units/L]; biopsy showed cirrhosis; patient developed progressive renal failure and died, possibly had underlying chronic hepatitis C).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R28">Rigberg LA, Robinson MJ, Espiritu CR. Chlorpropamide-induced granulomas. A probable hypersensitivity reaction in liver and bone marrow. JAMA 1976; 235: 409-10.  [<a href="/pubmed/128640" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 128640</span></a>]<div><i>(62 year old woman developed rash, fever and eosinophilia 2 weeks after starting chlorpropamide [bilirubin 0.8 mg/dL, AST 135 U/L, Alk P 405 U/L], liver and bone marrow biopsies showed granulomas; repeat biopsies in follow up were normal).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R29">Frier BM, Stewart WK. Cholestatic jaundice following chlorpropamide self-poisoning. Clin Toxicol 1977; 11: 13-7.  [<a href="/pubmed/872537" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 872537</span></a>]<div><i>(19 year old woman took an overdose of chlorpropamide and required 6 days of iv glucose; developing nausea at 14 and jaundice at 21 days [bilirubin 6.6 mg/dL, Alk P ~2 times ULN, AST 124 U/L, GGT 50 U/L], resolving over subsequent 4 weeks).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R30">LoIudice TA, Lang JA. Tolazamide-induced hepatic dysfunction. Am J Gastroenterol 1978; 69: 81-3.  [<a href="/pubmed/645691" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 645691</span></a>]<div><i>(33 year old man developed abnormal liver tests on tolazamide, latency unclear [bilirubin 1.4 mg/dL, AST 150 U/L, Alk P 1392 U/L], biopsy showed inflammation without cholestasis or necrosis; positive rechallenge).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R31">Ingelmo M, Vivancos J, Bruguera M, Sierra J, Balcells A. [Hypersensitivity vasculitis and granulomatous hepatitis induced by glybenclamide: a case report]. Med Clin (Barcelona) 1980; 75: 306-8.  [<a href="/pubmed/6776355" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6776355</span></a>]<div><i>(51 year old man developed fever, rash, fatigue and eosinophilia arising after uncertain period of glibenclamide therapy [bilirubin 0.6 mg/dL, AST 57 U/L, Alk P 4 times ULN, GGT 355 U/L], granulomas on liver biopsy, resolved when glibencamide was stopped; follow up liver biopsy normal).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R32">Bridges ME, Pittman FE. Tolazamide-induced cholestasis. South Med J 1980; 73: 1072-4.  [<a href="/pubmed/7403921" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7403921</span></a>]<div><i>(54 year old woman developed jaundice 15 months after starting chlorpropamide [bilirubin 14 mg/dL; ALT 225 U/L, Alk P 180 U/L], rapid recovery upon withdrawal, but rapid recurrence upon starting tolazamide [bilirubin 21 mg/dL, ALT 26 U/L, Alk P 306 U/L] and slow recovery).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R33">Gill MJ, Ratliff DA, Harding LK. Hypoglycemic coma, jaundice, and pure RBC aplasia following Chlorpropamide therapy. Arch Intern Med 1980; 140: 714-5.  [<a href="/pubmed/7396601" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7396601</span></a>]<div><i>(41 year old woman developed hypoglycemia, anemia and mild cholestatic liver injury 4 weeks after starting chlorpropamide [bilirubin 2.2 mg/dL, Alk P 890 U/L, AST 316 U/L], resolving within 6 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R34">Wongpaitoon V, Russell RF, Mills PR, Patrick RS. Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy. Postgrad Med J 1981; 57: 244.  [<a href="/pmc/articles/PMC2425002/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2425002</span></a>] [<a href="/pubmed/6794018" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6794018</span></a>]<div><i>(61 year old man developed severe hypoglycemia 5 months after starting glyburide with concurrent rash [bullae] and cholestatic hepatitis [bilirubin 3.2 mg/dL, ALT 146 U/L, Alk P 2420 U/L], resolving rapidly within a month of stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R35">Bell RL. Chlorpropamide hepatitis. Ala Med 1984; 53: 20, 22-3.  [<a href="/pubmed/6731219" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6731219</span></a>]<div><i>(Two cases and literature review; jaundice arose after 4 and 3 weeks of chlorpropamide therapy [bilirubin 12.5 and 4.9 mg/dL, AST 670 and 200 U/L, Alk P 349 and 161 U/L], resolving within 1-2 months of stopping, biopsy showing cholestatic hepatitis).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R36">Schneider HL, Hornbach KD, Kniaz JL, Efrusy ME. Chlorpropamide hepatotoxicity: report of a case and review of the literature. Am J Gastroenterol 1984; 79: 721-4.  [<a href="/pubmed/6475904" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6475904</span></a>]<div><i>(52 year old woman developed rash followed by jaundice beginning 2 weeks after starting chlorpropamide [bilirubin 0.8 rising to 2.6 mg/dL, ALT 456 U/L, Alk P 130 rising to 858 U/L]; review of literature indicating latency of 2-5 weeks, cholestatic enzyme pattern and eosinophila in 50% of cases).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R37">Rumboldt Z, Bota B. Favorable effects of glibenclamide in a patient exhibiting idiosyncratic hepatotoxic reactions to both chlorpropamide and tolbutamide. Acta Diabetol Latina 1984; 2: 387.  [<a href="/pubmed/6442088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6442088</span></a>]<div><i>(42 year old woman developed rash, fever and jaundice 4 weeks after starting chlorpropamide and after a few days of ampicillin [bilirubin 1.6 rising to 4.4 mg/dL, AST 178 U/L, Alk P 1.7 rising to 15 times ULN, GGT 202, eosinophils 20%], finally resolving with stopping chlorpropamide; with immediate positive rechallenge to chlorpropamide, delayed recurrence to tolbutamide, but not glyburide: Case 1).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R38">Baciewicz AM, Dattilo R, Willis SE, Kershaw JL. Jaundice and rash associated with chlorpropamide. Diabetes Care 1985; 8: 200-1.  [<a href="/pubmed/3158501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3158501</span></a>]<div><i>(42 year old woman developed jaundice 4 weeks after starting chlorpropamide [bilirubin 8.6 mg/dL, AST 165 U/L, GGT 625 U/L], resolving rapidly upon stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R39">Gupta R, Sachar DB. Chlorpropamide-induced cholestatic jaundice and pseudomembranous colitis. Am J Gastroenterol 1985; 80: 381-3.  [<a href="/pubmed/2859803" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2859803</span></a>]<div><i>(59 year old man developed jaundice 4 weeks after starting chlorpropamide [bilirubin 7.0 mg/dL, ALT 332 U/L, Alk P 542 U/L], course complicated by pseudomembranous colitis).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R40">Nakao NL, Gelb AM, Stenger RJ, Siegel JH. A case of chronic liver disease due to tolazamide. Gastroenterology 1985; 89: 192-5.  [<a href="/pubmed/4007403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4007403</span></a>]<div><i>(81 year old woman tolerated chlorpropamide for 2 years, but developed cholestatic liver injury 3 weeks after being switched to tolazamide [bilirubin 22 mg/dL, ALT 63 U/L, Alk P 362 U/L]; slow recovery and persistence of abnormal ALT [79 U/L] and Alk P [258 U/L] with liver biopsy showing portal inflammation and duct injury and possibly loss).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R41">Clementsen P, Hansen CL, H&#x000f8;egholm A. [Glipizide induced toxic hepatitis] Ugeskr Laeger 1986; 148: 771-2. Danish.  [<a href="/pubmed/3705214" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3705214</span></a>]<div><i> (72 year old woman developed jaundice 3.5 months after starting glipizide [bilirubin 17.2 mg/dL, ALT 1288 U/L, Alk P 367 U/L], with subsequent worsening and death 14 days later despite stopping glipizide].</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R42">Goodman RC, Dean PJ, Radparvar A, Kitabchi AE. Glyburide-induced hepatitis. Ann Intern Med 1987; 106: 837-9.  [<a href="/pubmed/3107448" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3107448</span></a>]<div><i>(Two women, ages 61 and 63 years, developed jaundice 1 and 4 weeks after starting glyburide [bilirubin 14.5 and 4.1 mg/dL, AST 60 and 17 times ULN, Alk P 1.7 and 3 times ULN], resolving within few months of stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R43">Geubel AP, Nakad A, Rahier J, Dive C. Prolonged cholestasis and disappearance of interlobular bile ducts following chlorpropamide and erythromycin ethylsuccinate. Case of drug interaction? Liver 1988; 8: 350-3.  [<a href="/pubmed/3265170" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3265170</span></a>]<div><i>(52 year old man developed fever, rash, eosinophilia and jaundice [bilirubin 8.0 mg/dL, ALT 159 U/L, Alk P 1156 U/L] followed by vanishing bile duct syndrome, cirrhosis and death within 2 years of onset after 3 weeks of erythromycin ethylsuccinate, but also 4 months of chlorpropamide; issue of whether one or both agents was responsible).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R44">Rank JM, Olson RC. Reversible cholestatic hepatitis caused by acetohexamide. Gastroenterology 1989; 96: 1607-8.  [<a href="/pubmed/2714585" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2714585</span></a>]<div><i>(75 year old woman developed jaundice 17 months after starting acetohexamide, but shorting after an increase in dose [bilirubin 7.0 mg/dL, AST 149 U/L, Alk P 567 U/L], resolving rapidly upon stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R45">Meadow P, Tullio CJ. Glyburide-induced hepatitis. Clin Pharm 1989; 8: 470.  [<a href="/pubmed/2502355" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2502355</span></a>]<div><i>(54 year old man found to have asymptomatic rise in Alk P [66 to 220 U/L] and ALT [33 to 151 U/L] one week after raising chronic glyburide dose from 5 to 20 mg daily; rapid resolution on stopping glyburide).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R46">van Basten JP, van Hoek B, Zeijen R, Stockbr&#x000fc;gger R. Glyburide-induced cholestatic hepatitis and liver failure. Case-report and review of the literature. Neth J Med 1992; 40: 305-7.  [<a href="/pubmed/1436270" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1436270</span></a>]<div><i>(69 year old woman developed jaundice 10 weeks after starting glyburide [bilirubin 6.9 mg/dL, ALT 405 U/L, Alk P 610 U/L], subsequently progressing to hepatic failure and death, possibly due to delayed stopping of drug).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R47">P&#x000e9;rez-Rold&#x000e1;n F, Aguirre A, Ba&#x000f1;ares R, Casado M, Gonz&#x000e1;lez-Asanza C, Alvarez E, Clemente G. [Cholestatic hepatitis caused by glybenclamide in a patient with hepatitis C virus]. Rev Esp Enf Digest 1995; 87: 174-6.  [<a href="/pubmed/7748712" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7748712</span></a>]<div><i>(68 year old man with chronic hepatitis C developed jaundice 10 weeks after starting glyburide [bilirubin 26.4 mg/dL, ALT 920 U/L, Alk P 651 U/L], resolving upon stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R48">Krivoy N, Zaher A, Yaacov B, Alroy G. Fatal toxic intrahepatic cholestasis secondary to glibenclamide. Diabetes Care 1996; 19: 385-6.  [<a href="/pubmed/8729168" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8729168</span></a>]<div><i>(69 year old woman developed severe cholestatic hepatitis after 7 years of glyburide therapy, but 2 weeks after dose increase [15/mg/day] [bilirubin 5.0 rising to 49 mg/dL, peak ALT 87 U/L, Alk P 583 U/L], subsequently developing progressive hepatic failure and death).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R49">Kaminski CA, Angueira E. Chlorpropamide-induced cholestatic liver failure resulting in death. Endocr Pract 1996; 2: 191-2.  [<a href="/pubmed/15251538" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15251538</span></a>]<div><i>(81 year old man developed nausea and jaundice 4 weeks after starting chlorpropamide [bilirubin 15.2 mg/dL, ALT 255 U/L, Alk P 902 U/L], with subsequent multiorgan failure and death).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R50">Saw D, Pitman E, Maung M, Savasatit P, Wasserman D, Yeung CK. Granulomatous hepatitis associated with glyburide. Dig Dis Sci 1996; 41: 322-5.  [<a href="/pubmed/8601376" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8601376</span></a>]<div><i>(46 year old woman was found to have granulomas on liver biopsy done during a cholecystectomy, having been on glyburide for 3 years [bilirubin 1.4 mg/dL, ALT 41 U/L, Alk P 179 U/L]; minor elevations in Alk P persisted after withdrawal and possibly represented nodular regenerative hyperplasia).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R51">Petrogiannopoulos C, Zacharof A. Glibenclamide and liver disease. Diabetes Care 1997; 20: 1215.  [<a href="/pubmed/9203475" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9203475</span></a>]<div><i>(64 year old man developed jaundice and pruritus 2 months after starting glyburide [bilirubin 10.0 mg/dL, ALT 310 U/L, Alk P 150 U/L], with resolution on stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R52">Tholakanahalli VN, Potti A, Heyworth MF. Glibenclamide-induced cholestasis. West J Med 1998; 168: 274-7.  [<a href="/pmc/articles/PMC1304962/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1304962</span></a>] [<a href="/pubmed/9584675" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9584675</span></a>]<div><i>(64 year old man developed jaundice after 4 years of glyburide therapy [peak bilirubin 19.8 mg/dL, Alk P 263 U/L, ALT 109 U/L], resolving within 3 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R53">Crespo Valad&#x000e9;s E, Ortega G&#x000f3;mez A, Alvarado Izquierdo MI, Magro Ledesma D. [Hepatotoxic reaction associated with metformin and chlorpropamide treatment] Rev Clin Esp 1999; 199: 118-9. Spanish.  [<a href="/pubmed/10216414" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10216414</span></a>]<div><i>(68 year old woman developed an acute immunoallergic reaction 2 days after starting metformin with fever, eosinophilia, rash and lymphadenopathy accompanied by a mild cholestatic hepatitis [bilirubin 2.2 mg/dL, ALT 327 U/L, Alk P 2553 U/L], with rapid resolution on stopping therapy; patient was also on long term chlorpropamide).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R54">Dusoleil A, Condat B, Sobesky R, Pelletier G, Buffet C. [Glimepiride-induced acute hepatitis] Gastroenterol Clin Biol 1999; 23: 1096-7. French.  [<a href="/pubmed/10592884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10592884</span></a>]<div><i>(61 year old woman developed dizziness and weakness 3 months after starting glimepiride [bilirubin 2.0 mg/dL, ALT 27 times ULN, Alk P normal], resolving 6 weeks after stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R55">Dourakis SP, Tzemanakis E, Sinani C, Kafiri G, Hadziyannis SJ. Gliclazide-induced acute hepatitis. Eur J Gatroenterol Hepatol 2000; 12: 119-121.  [<a href="/pubmed/10656221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10656221</span></a>]<div><i>(60 year old woman developed acute hepatitis 5 weeks after starting gliclazide [bilirubin 3.9 mg/dL, ALT 636 U/L, Alk P 365 U/L, GGT 947 U/L], tests returning to normal within 6 weeks despite switching to glibenclamide [glyburide]).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R56">Sitruk V, Mohib S, Grando-Lemaire V, Ziol M, Trinchet JC. [Acute cholestatic hepatitis induced by glimepiride] Gastroenterol Clin Biol 2000; 24: 1233-4. French.  [<a href="/pubmed/11173739" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11173739</span></a>]<div><i>(61 year old man with a history of alcoholism developed cholestatic hepatitis 10 weeks after starting glimepiride [bilirubin 21.1 mg/dL, ALT 4 times ULN, Alk P 5 times ULN], resolving within 8 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R57">Caksen H, Kendirci M, Tutus A, Uz&#x000fc;m K, Kurtoglu S. Gliclazide-induced hepatitis, hemiplegia and dysphasia in a suicide attempt. J Pediatr Endocrinol Metab 2001; 14: 1157-9.  [<a href="/pubmed/11592575" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11592575</span></a>]<div><i> (14 year old girl developed liver injury after an overdose of gliclazide [15 tablets] and severe tonic-clonic seizures [bilirubin 4.6 mg/dL, ALT 102 U/L, Alk P 63 U/L, glucose 15 mg/dL], liver test abnormalities resolving within 3 weeks, but she was left with residual brain damage and hemoplegia).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R58">Chitturi S, Le V, K.<div><i>ench J, Loh C, George J. Gliclazide-induced acute hepatitis with hypersensitivity features. Dig Dis Sci 2002; 47: 1107-10. <a href="https://www.ncbi.nlm.nih.gov/pubmed/12018908" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a> (42 year old woman developed rash 4 weeks after starting gliclazide and metformin followed by jaundice at 6 weeks [bilirubin 2.9 mg/dL, ALT 1605 U/L, Alk P 158 U/L], which did not improve until gliclazide was stopped and then resolved within 6 weeks and did not recur upon reintroduction of metformin: Case 2).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R59">Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22: 169-83.  [<a href="/pubmed/12016548" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12016548</span></a>]<div><i>(Review of hepatotoxicity of antidiabetic agents, mentions that all of the sulfonylureas have been implicated in liver toxicity; that fever, rash and eosinophilia may be present suggesting an immunoallergic cause).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R60">Chan KA, Truman A, Gurwitz JH, Hurley JS, Martinson B, Platt R, Everhart JE, et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med 2003; 163: 728-34.  [<a href="/pubmed/12639207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12639207</span></a>]<div><i>(Industry supported retrospective cohort study of 5 health maintenance organizations databases found low rates of severe liver injury [0.06-0.10/1000 person years] with all oral antidiabetic medications: sulfonylureas, metformin and troglitazone).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R61">Ilario MJ, Turyan HV, Axiotis CA. Glipizide treatment with short-term alcohol abuse resulting in subfulminant hepatic failure. Virchows Arch 2003; 443: 104-5.  [<a href="/pubmed/12719973" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12719973</span></a>]<div><i>(50 year old with a history of alcohol abuse developed severe hepatitis 19 weeks after starting glipizide [bilirubin 10.2 mg/dL, ALT 2662 U/L, Alk P 232 U/L], glipizide was continued and patient developed acute liver failure and died several weeks later).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R62">Heurgu&#x000e9; A, Bernard-Chabert B, Higuero T, Lukas-Croisier C, Caron J, Cadiot G, Thi&#x000e9;fin G. [Glimepiride-induced acute cholestatic hepatitis] Ann Endocrinol(Paris) 2004; 65: 174-5. French.  [<a href="/pubmed/15247878" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15247878</span></a>]<div><i>(54 year old man developed jaundice 2 weeks after starting glimepiride [bilirubin 16.8 mg/dL, ALT 12 times ULN, Alk P 7 times ULN], resolving within 2 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R63">Chounta A, Zouridakis S, Ellinas C, Tsiodras S, Zoumpouli C, Kopanakis S, Giamarellou Hl. Cholestatic liver injury after glimepiride therapy. J Hepatol 2005; 42: 944-6.  [<a href="/pubmed/15885370" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15885370</span></a>]<div><i>(65 year old man developed jaundice 2 weeks after starting glimepiride [bilirubin 6.9 mg/dL, ALT 141 U/L, Alk P 403 U/L], with positive rechallenge, delaying recovery to ~3 months).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R64">Bj&#x000f6;rnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005; 40: 1095-101.  [<a href="/pubmed/16165719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16165719</span></a>]<div><i>(Survey of all cases of DILI with fatal outcome from Swedish Adverse Drug Reporting system from 1966-2002; 103 cases identified as highly probable, probable or possible, but none were attibuted to sulfonylureas).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R65">Spiller HA, Sawyer TS. Toxicology of oral antidiabetic medications. Am J Health Syst Pharm 2006; 63: 929-38.  [<a href="/pubmed/16675650" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16675650</span></a>]<div><i>(Review on safety of oral antidiabetic medications focusing upon hypoglycemia and overdose; little information on hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R66">Sabat&#x000e9; M, Ib&#x000e1;&#x000f1;ez L, P&#x000e9;rez E, Vidal X, Buti M, Xiol X, Mas A, et al. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther 2007; 25: 1401-9.  [<a href="/pubmed/17539979" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17539979</span></a>]<div><i>(Among 126 cases of acute liver injury from medications in a population based survey, glyburide accounted for 8 cases, relative risk of 6.1 and had an estimated incidence rate of 3.3/100,000 person years of exposure).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R67">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, one case was attributed to glipizide and one to Glucovance [metformin and glyburide]).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R68">Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf 2009; 32: 787-800.  [<a href="/pubmed/19670918" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19670918</span></a>]<div><i>(Observational cohort study of 2097 patients with diabetes randomized to received either glyburide or pioglitazone and followed for 3 years; adverse hepatic events [ALT &#x0003e;3 times ULN] occurred in 0.38% of the glyburide group, but in none of the pioglitazone group).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R69">Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.  [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 [11%] were attributed to drug induced liver injury, of which 4 were due to troglitazone, but none to other antidiabetic medications).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R70">Drugs for type 2 diabetes. Treat Guidel Med Lett 2011; 9 (108): 47-54.  [<a href="/pubmed/21778966" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21778966</span></a>]<div><i> (Concise review of the role of current antidiabetic medications in management of type 2 diabetes).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R71">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced lLiver injury in the General population of Iceland. Gastroenterology 2013; 144: 1419-25.  [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were due to sulfonylureas or other antidiabetic medications).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R72">Ridderstr&#x000e5;le M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2: 691-700.  [<a href="/pubmed/24948511" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24948511</span></a>]<div><i>(1549 patients with diabetes inadequately controlled on metformin, were randomly assigned to be treated with the addition of empagliflozin or glimepiride for 2 years; improvements in HbA1c and adverse events were both similar in both groups; reasons for discontinuation of glimepiride in 34 patients included one case of hepatitis and one of jaundice with no further details; no mention of change in ALT levels).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R73">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol 2014; 13: 231-9.  [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i> (Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, none of which were attributed to a sulfonylurea or other antidiabetic medications).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R74">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 4 [0.5%] were attributed to antidiabetic medications include 2 to metformin, 1 sitagliptin and 1 glyburide [transient rise of ALT to a peak of 629 U/L without change in bilirubin, 3 months after starting glyburide and shortly after receiving doxycycline]).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R75">Feng W, Gao C, Bi Y, Wu M, Li P, Shen S, Chen W, et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease. J Diabetes 2017; 9: 800-9.  [<a href="/pubmed/28332301" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28332301</span></a>]<div><i>(Among 93 patients with type 2 diabetes treated with gliclazide, liraglutide or metformin for 24 weeks, fasting blood glucose, HgA1c and ALT levels decreased in all 3 groups, but weight loss of decrease in intrahepatic fat [measured by ultrasound] decreased more with liraglutide and metformin; no mention of ALT increases or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R76">Campos MG, Machado J, Costa ML, Lino S, Correia F, Maltez F. Case report: Severe hematological, muscle and liver toxicity caused by drugs and artichoke infusion interaction in an elderly polymedicated patient. Curr Drug Saf 2017 Sep 12. [Epub ahead of print].  [<a href="/pubmed/28901251" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28901251</span></a>]<div><i>(Adult male developed muscle pains and ALT elevations after a 1.5 liter infusion of artichoke juice and while taking medications for diabetes [including gliclazide] and hypertension [enalopril and diuretics] which the authors attributed to herb-drug interactions and involvement of CYP 3A4 and 2C9).</i></div></div></li><li><div class="bk_ref" id="Sulfonylureas.R77">Drugs for type 2 diabetes. Med Lett Drugs Ther 2017; 59 (1512): 9-18.  [<a href="/pubmed/28076339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28076339</span></a>]<div><i>(Concise review of the role of current antidiabetic medications for type 2 diabetes mentions that the sulfonylureas [glimepiride, glipizide, glyburide] are "reasonable" second-line agents that reduce HbA1c levels by 1% to 1.5%, and long term therapy reduces the risk of micro- and macro-vascular complications of diabetes without increasing the risk of myocardial infarction or stroke; the first generation sulfonylureas are not mentioned).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548361</span><span class="label">PMID: <a href="/pubmed/31643682" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643682</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Sulfonamides/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/FstGenSulfonylureas/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548361&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548361/?report=reader">PubReader</a></li><li><a href="/books/NBK548361/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548361" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548361" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Sulfonylureas. [Updated 2018 Mar 16].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548361/pdf/Bookshelf_NBK548361.pdf">PDF version of this page</a> (169K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(sulfonylureas/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%222009/12/01%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Sulfonylureas: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=sulfonylureas" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Sulfonylureas: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4860344" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4860344" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/6781341" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">The pharmacology of sulfonylureas.</a><span class="source">[Am J Med. 1981]</span><div class="brieflinkpop offscreen_noflow">The pharmacology of sulfonylureas.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Skillman TG, Feldman JM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Med. 1981 Feb; 70(2):361-72. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15099124" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.</a><span class="source">[Pharmacoeconomics. 2004]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Plosker GL, Figgitt DP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pharmacoeconomics. 2004; 22(6):389-411. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/6435940" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.</a><span class="source">[Clin Pharm. 1984]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Prendergast BD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Pharm. 1984 Sep-Oct; 3(5):473-85. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25466239" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Mortality risk among sulfonylureas: a systematic review and network meta-analysis.</a><span class="source">[Lancet Diabetes Endocrinol. 2015]</span><div class="brieflinkpop offscreen_noflow">Mortality risk among sulfonylureas: a systematic review and network meta-analysis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Lancet Diabetes Endocrinol. 2015 Jan; 3(1):43-51. Epub 2014 Oct 22.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29802958" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.</a><span class="source">[Diabetes Res Clin Pract. 2018]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Colagiuri S, Matthews D, Leiter LA, Chan SP, Sesti G, Marre M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Diabetes Res Clin Pract. 2018 Sep; 143:1-14. Epub 2018 May 24.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643682" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643682" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="&#10;                        HTOn&#10;                    "><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T16:16:35-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal101&amp;ncbi_phid=CE88592A046891910000000002A900BE&amp;ncbi_session=CE88592A04694311_0681SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548361%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548361&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548361/&amp;ncbi_pagename=Sulfonylureas - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88592A04694311_0681SID /projects/books/PBooks@9.2 portal101 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>